google.com, pub-5475981771945671, DIRECT, f08c47fec0942fa0

WorldFuture and humanity

Data from registrational study of Sugemalimab cell lung cancer published
cell lung cancer

Data from registrational study of Sugemalimab cell lung cancer published

SUZHOU, China, Jan. 15, 2022– CStone Pharmaceuticals (HKEX: 2616), a leading biopharmaceutical company, today announced that the registrational clinical data from sugemalimab (the GEMSTONE-301 study) in stage III non-small cell lung cancer (NSCLC) were published in the world-leading clinical oncology journal, The Lancet Oncology.  Sugemalimab as a consolidation therapy demonstrated
3 min read